In situ MUC1-specific CAR engineering of tumor-supportive macrophages stimulates tumoricidal immunity against pancreatic adenocarcinoma

Liu, Ying; Jing, Weiqiang; Zhang, Jing; Chen, Chen; Gao, Lin; Shi, Chongdeng; Li, Anning; Sun, Peng; Zhang, Rui; Yang, Zhenmei; Tang, Chunwei; Du, Wei; Dong, Yuanmin; Xu, Jie; Zhao, Kun; Jiang, Xinyi

doi:10.1016/j.nantod.2023.101805

Cited by 3 publications

(1 citation statement)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Later, following the same design principle, the research group successfully reprogrammed tumor-associated macrophages to CAR-M against ErbB2, or mucin 1 tumor antigens. [74,75] Most recently, the same group reported a unique implant nanoparticle that locoregionally yielded CAR-M targeting Staphylococcus aureus to prevent periprosthetic joint infection. [76]…”

Section: Nanomaterials For Plasmid Dna Deliverymentioning

confidence: 99%

In Situ Reprogramming of Immune Cells Using Synthetic Nanomaterials

Nie,

Qin,

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

In the past decade, adoptive cell therapy with chimeric antigen receptor‐T (CAR‐T) cells has revolutionized cancer treatment. However, the complexity and high costs involved in manufacturing current adoptive cell therapy greatly inhibit its widespread availability and access. To address this, in situ cell therapy, which directly reprograms immune cells inside the body, has recently been developed as a promising alternative. Here, we provide an overview of the recent progress in the development of synthetic nanomaterials to deliver plasmid DNA or mRNA for in situ reprogramming of T cells and macrophages, focusing especially on in situ CAR therapies. Also, we discuss the main challenges for in situ immune cell reprogramming and propose some approaches to overcome these barriers to fulfill the clinical applications.This article is protected by copyright. All rights reserved

show abstract

Section: Nanomaterials For Plasmid Dna Deliverymentioning

confidence: 99%